Reports about: NYMX
Short NYMX. This offshore “biotech” promotion will go to zero (yes, zero)
August 9, 2016
Summary Nymox withheld the data that Phase 3 trials of its only drug had failed for 6-12 months after management knew of the failure. During this time, Nymox issued bullish...